23
Jan
2023
Category: Blog
9
Jan
2023
Bionest
Happy 2023! – A Few Thoughts on the New Year Ahead
More M&A and corporate strategic changes? Advances in Alzheimers? New offerings for NASH & depression? We take a peek into what to expect in pharma in 2023.
19
Dec
2022
Bionest
COVID Vaccines Transition from Government Supply to Private Marketplace
What will be the impact of moving COVID vaccines to the private marketplace? We examine both the challenges and new opportunities for the companies.
5
Dec
2022
Bionest
Medicare Drug Price Negotiations: Potential Impacts
What impact will the Inflation Reduction Act have on pharma & biotech companies and what should they consider in their pipeline development plans?
21
Nov
2022
Bionest
Competitors Collaborate to Understand Shared DMD Adverse Event
Adverse responses to experimental gene therapies for Duchenne muscular dystrophy leads to unique collaboration between pharma competitors.
7
Nov
2022
Bionest
Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals
Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
24
Oct
2022
Bionest
A New Advance in the Treatment of Major Depressive Disorder
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
10
Oct
2022
Bionest
Are the Blues Ending for Bluebird?
Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
26
Sep
2022
Bionest
ASCO 2022 – Part 2: Vanishing dMMR Rectal Cancer; Predicting Cytokine Release Syndrome Risk
Could dostarlima spare some colorectal cancer patients from chemo? Is it possible to predict which CAR-T patients are at risk of CRS? More ASCO highlights.
19
Sep
2022